Physician profile
Thomas Puzio
NPI 1609073196
$959.52
in general payments reported to CMS, 2019-2025
12 companies · $23.32 in 2025
The $23.32 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $322 · 2021: $134 · 2022: $314 · 2023: $15.11 · 2025: $23.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $229.72 | 2019-2022 | |
| Edwards Lifesciences Corporation | $189.14 | 2020 | |
| Abiomed | $124.96 | 2022 | |
| Merck Sharp & Dohme LLC | $120.32 | 2019-2022 | |
| Avanos Medical | $66.70 | 2019-2021 | |
| Heron Therapeutics, INC. | $50.62 | 2021-2022 | |
| Chiesi USA, INC. | $42.83 | 2019-2023 | Cleviprex |
| Werfen USA LLC | $38.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $37.57 | 2020-2025 | Terlivaz |
| Ambu INC. | $30.38 | 2020 | |
| Trevena, INC. | $14.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Puzio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.